Developer docs
API playgroundTry for free, no card

Search company profiles

Pendopharm

Full company profile

uuid00088vm

Namestring
Pendopharm
Legal namestring
PENDOPHARM, Division of Pharmascience Inc.
Websiteurl
pendopharm.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Pendopharm is the branded specialty pharmaceutical division of Pharmascience Inc., a privately held Canadian pharmaceutical company founded in 1983 and headquartered in Montreal, Quebec. Established in 2010 as Pharmascience's specialty-branded arm, Pendopharm develops, in-licenses, and commercializes 40+ specialty pharmaceutical products across four therapeutic areas: gastroenterology, sports medicine and orthopedics, neurology, and cardiology. The product portfolio includes branded specialty prescription drugs (Yorvipath for hypoparathyroidism, GLATECT for multiple sclerosis, Cingal/Monovisc/Orthovisc/SportVis for osteoarthritis and tendon/ligament pain), first-in-Canada pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam), gastrointestinal therapies (Octasa, ELEVIEW), and consumer health products (PHARIXIA, PrPERICHLOR).

Pendopharm's business model is built on exclusive distribution and licensing partnerships with international pharmaceutical innovators — including Ascendis Pharma, Anika Therapeutics, KalVista Pharmaceuticals, Neuraxpharm, Cosmo Pharmaceuticals, and Synthon — under which Pendopharm manages Health Canada regulatory approval and Canadian commercialization in exchange for distribution rights. Revenue derives from product sales through Canadian pharmaceutical wholesalers, specialty pharmacy channels, and direct institutional sales, with reimbursement secured via all major provincial drug formularies (Ontario, Alberta, Quebec, Saskatchewan, Manitoba, New Brunswick, British Columbia) and private insurers. Patient support programs such as the Ally Patient Support Program provide injection training, reimbursement assistance, and financial support.

The company leverages its parent Pharmascience's GMP manufacturing infrastructure and 1,500-employee operational base, while operating a dedicated specialty field force targeting endocrinologists, neurologists, gastroenterologists, sports medicine specialists, and other healthcare professionals. Customer engagement runs through medical information services, continuing education programs (webinars, tele-expertise), and healthcare professional communications, with no disclosed direct-to-consumer channels. Pricing is not publicly disclosed; products are reimbursed under public and private drug plans rather than sold on a transactional consumer basis.

Short descriptiontext

Pendopharm is the branded specialty pharmaceutical division of Montreal-based Pharmascience Inc., commercializing 40+ specialty prescription drugs, pediatric formulations, and consumer health products across gastroenterology, orthopedics, neurology, and cardiology in Canada through exclusive licensing partnerships with international pharmaceutical innovators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, prescription drug distribution, gastroenterology treatments, viscosupplementation products, pediatric formulations
Industry5 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAMAA
Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Specialty Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Specialty Pharmaceutical Product Sales
TypeOne Time License
Description

Pendopharm generates revenue through commercialization of specialty prescription medicines and consumer brands in Canada. The company develops, in-licenses and commercializes innovative products across four core therapeutic areas.

pendopharm.com
2Exclusive Distribution Agreements
TypeLicensing Royalties
Description

Pendopharm enters into exclusive distribution agreements with international pharmaceutical companies to manage regulatory approval and commercialization of products in Canada, receiving distribution rights in exchange for local market expertise and commercialization capabilities.

pendopharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1PrPERICHLOR
Description

Alcohol-free gingivitis oral rinse for professional treatment of moderate to severe gingivitis

pendopharm.com
+5 more records
Core offering1 text field

Pendopharm develops, in-licenses and commercializes specialty pharmaceutical products in Canada across four core therapeutic areas: gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Its portfolio of more than 40 specialty products includes branded prescription drugs (Yorvipath, GLATECT, Octasa, IBAVYR), viscosupplementation treatments (Cingal, Monovisc, Orthovisc, SportVis), endoscopic procedural products (ELEVIEW), pediatric formulations, and consumer oral-care brands. The company secures exclusive Canadian distribution rights from international innovators and manages regulatory approval, market access, and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • More than 40 specialty products across multiple therapeutic areas
+1 more record
Product overview1 text field

Pendopharm is a Canadian specialty pharmaceutical company offering a diversified portfolio of specialty prescription drugs, pediatric formulations, and consumer health products. The company's specialty products span four core therapeutic areas: gastroenterology (including Octasa® for IBD and ELEVIEW™ for endoscopic procedures), sports medicine & orthopedics (including SportVis™, Cingal®, Monovisc®, and Orthovisc® for hyaluronic acid-based treatments), neurology (including GLATECT™ for MS and prpdp-LevETIRAcetam for epilepsy), and cardiology (including Yorvipath® for hypoparathyroidism). Pendopharm also focuses on unmet medical needs through pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam) and consumer health products (PHARIXIA, PrPERICHLOR®). The company operates primarily through distribution partnerships with international pharmaceutical companies to commercialize innovative medicines in Canada.

Product and service5 records
1Yorvipath® (palopegteriparatide injection)
CategorySpecialty prescription drug
Description

Parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism in adults, developed by Ascendis Pharma and commercialized in Canada by Pendopharm under an exclusive distribution agreement.

2Buccolam®
CategorySpecialty prescription drug
Description

Pediatric epilepsy treatment for buccal administration, commercialized in Canada by Pendopharm under an exclusive distribution agreement with Neuraxpharm.

3Sebetralstat
CategoryInvestigational specialty drug
Description

Investigational oral on-demand therapy for Hereditary Angioedema (HAE), distributed in Canada under exclusive agreement with KalVista Pharmaceuticals.

4Cingal® / Monovisc® / Orthovisc®
CategorySpecialty prescription drug
Description

Hyaluronic acid-based viscosupplementation products for the treatment of osteoarthritis pain. Cingal is a next-generation single-injection non-opioid treatment; Monovisc and Orthovisc are single-injection viscosupplementation therapies.

5Octasa® (oral mesalamine)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Neuraxpharm
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-04
Description

Exclusive distribution agreement for Buccolam in Canada. Buccolam received Health Canada approval and was commercialized in February 2026. Neuraxpharm is a pharmaceutical company specializing in CNS treatments.

pendopharm.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-26
Description

Exclusive distribution agreement for sebetralstat, an investigational oral therapy for Hereditary Angioedema (HAE). Under regulatory review in multiple countries, sebetralstat would become the first oral on-demand treatment for HAE in Canada. Financial terms not disclosed.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-09
Description

Exclusive distribution agreement where Pendopharm is responsible for regulatory approval and commercialization of TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism in Canada. Yorvipath received Health Canada approval in February 2026. Ascendis is a global biopharma company headquartered in Copenhagen, Denmark (NASDAQ: ASND).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-16
Description

Renewal of exclusive distribution agreement for Cingal, Monovisc, and Orthovisc through end of 2030. Partnership since 2012. Anika is a global joint preservation company (NASDAQ: ANIK) providing hyaluronic acid-based therapeutic solutions. Cingal is a next-generation non-opioid treatment for osteoarthritis pain.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-07-31
Description

Distribution partnership for ELEVIEW, the first all-in-one submucosal injectable composition for endoscopic resection procedures. Cosmo is a specialty pharma company focused on GI disorders and endoscopy. ELEVIEW is manufactured by Cosmo Technologies Ltd. in Dublin, Ireland and distributed by Pendopharm in Canada.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-09-29
Description

Partnership for GLATECT (glatiramer acetate for injection) launch in Canada for treatment of relapsing-remitting multiple sclerosis. Synthon is an international pharma company headquartered in the Netherlands with products approved in over 90 countries.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products in Canada and select international markets. Highly comparable business model to Pendopharm with focus on specialty therapeutic areas and exclusive distribution agreements.

TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products for the North American market. Comparable specialty pharma distribution model with similar therapeutic focus areas including CNS and cardiology.

TypeDirect peer
Description

Canadian specialty pharmaceutical company that commercializes specialty products through licensing and distribution partnerships. Directly comparable to Pendopharm in business model, therapeutic focus, and Canadian market focus.

TypeBroad incumbent
Description

Headquartered in Canada, Bausch Health is a large diversified specialty pharmaceutical company with significant Canadian operations. Comparable as a major Canadian pharma incumbent though much larger and broader in scope than Pendopharm.

5Acerus Pharmaceuticals
TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on commercializing novel prescription products. Similar size and Canadian market focus with licensing-driven business model.

6Medison Pharma
TypeDirect peer
Description

Canadian-headquartered specialty pharma company that provides commercial access for innovative therapies in Canada and Israel. Closely comparable in-licensing and distribution model focused on specialty therapeutic areas.

7AbbVie Canada
TypeBroad incumbent
Description

Major global pharmaceutical company with significant Canadian specialty pharma operations across immunology, neuroscience, and other therapeutic areas. Competes with Pendopharm's specialty portfolio offerings in Canada.

TypeBroad incumbent
Description

Canadian subsidiary of global pharma major Takeda, with strong specialty pharma presence in gastroenterology, neurology, and rare diseases. Directly overlaps with Pendopharm's core therapeutic areas.

TypeOthers
Description

Canadian specialty pharma services company providing commercialization, distribution, and patient support services. Comparable as a Canadian specialty pharma ecosystem participant, though services-focused rather than product-focused.

TypeRegional player
Description

Canadian pharmaceutical company headquartered in Quebec (like Pendopharm) with broad generic and specialty pharmaceutical portfolio. Comparable Quebec-based Canadian pharma with similar market scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pendopharm

Specialty Pharmaceuticalspendopharm.com

Pendopharm is the branded specialty pharmaceutical division of Montreal-based Pharmascience Inc., commercializing 40+ specialty prescription drugs, pediatric formulations, and consumer health products across gastroenterology, orthopedics, neurology, and cardiology in Canada through exclusive licensing partnerships with international pharmaceutical innovators.

What Pendopharm does

Pendopharm is the branded specialty pharmaceutical division of Pharmascience Inc., a privately held Canadian pharmaceutical company founded in 1983 and headquartered in Montreal, Quebec. Established in 2010 as Pharmascience's specialty-branded arm, Pendopharm develops, in-licenses, and commercializes 40+ specialty pharmaceutical products across four therapeutic areas: gastroenterology, sports medicine and orthopedics, neurology, and cardiology. The product portfolio includes branded specialty prescription drugs (Yorvipath for hypoparathyroidism, GLATECT for multiple sclerosis, Cingal/Monovisc/Orthovisc/SportVis for osteoarthritis and tendon/ligament pain), first-in-Canada pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam), gastrointestinal therapies (Octasa, ELEVIEW), and consumer health products (PHARIXIA, PrPERICHLOR).

Pendopharm's business model is built on exclusive distribution and licensing partnerships with international pharmaceutical innovators — including Ascendis Pharma, Anika Therapeutics, KalVista Pharmaceuticals, Neuraxpharm, Cosmo Pharmaceuticals, and Synthon — under which Pendopharm manages Health Canada regulatory approval and Canadian commercialization in exchange for distribution rights. Revenue derives from product sales through Canadian pharmaceutical wholesalers, specialty pharmacy channels, and direct institutional sales, with reimbursement secured via all major provincial drug formularies (Ontario, Alberta, Quebec, Saskatchewan, Manitoba, New Brunswick, British Columbia) and private insurers. Patient support programs such as the Ally Patient Support Program provide injection training, reimbursement assistance, and financial support.

The company leverages its parent Pharmascience's GMP manufacturing infrastructure and 1,500-employee operational base, while operating a dedicated specialty field force targeting endocrinologists, neurologists, gastroenterologists, sports medicine specialists, and other healthcare professionals. Customer engagement runs through medical information services, continuing education programs (webinars, tele-expertise), and healthcare professional communications, with no disclosed direct-to-consumer channels. Pricing is not publicly disclosed; products are reimbursed under public and private drug plans rather than sold on a transactional consumer basis.

Pendopharm firmographics

Firmographics
Name
Pendopharm
Legal name
PENDOPHARM, Division of Pharmascience Inc.
Website
https://pendopharm.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Pendopharm is the branded specialty pharmaceutical division of Montreal-based Pharmascience Inc., commercializing 40+ specialty prescription drugs, pediatric formulations, and consumer health products across gastroenterology, orthopedics, neurology, and cardiology in Canada through exclusive licensing partnerships with international pharmaceutical innovators.
Ownership category
akta.pro rank

Pendopharm industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAMAA
Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Specialty pharmaceuticals
  • Prescription drug distribution
  • Gastroenterology treatments
  • Viscosupplementation products
  • Pediatric formulations

Where Pendopharm is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Pendopharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Specialty Pharmaceutical Product Sales: Pendopharm generates revenue through commercialization of specialty prescription medicines and consumer brands in Canada. The company develops, in-licenses and commercializes innovative products across four core therapeutic areas.
  2. Exclusive Distribution Agreements: Pendopharm enters into exclusive distribution agreements with international pharmaceutical companies to manage regulatory approval and commercialization of products in Canada, receiving distribution rights in exchange for local market expertise and commercialization capabilities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Pendopharm product offering

Product offering

Core offering

Pendopharm develops, in-licenses and commercializes specialty pharmaceutical products in Canada across four core therapeutic areas: gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Its portfolio of more than 40 specialty products includes branded prescription drugs (Yorvipath, GLATECT, Octasa, IBAVYR), viscosupplementation treatments (Cingal, Monovisc, Orthovisc, SportVis), endoscopic procedural products (ELEVIEW), pediatric formulations, and consumer oral-care brands. The company secures exclusive Canadian distribution rights from international innovators and manages regulatory approval, market access, and commercialization.

Product overview

Pendopharm is a Canadian specialty pharmaceutical company offering a diversified portfolio of specialty prescription drugs, pediatric formulations, and consumer health products. The company's specialty products span four core therapeutic areas: gastroenterology (including Octasa® for IBD and ELEVIEW™ for endoscopic procedures), sports medicine & orthopedics (including SportVis™, Cingal®, Monovisc®, and Orthovisc® for hyaluronic acid-based treatments), neurology (including GLATECT™ for MS and prpdp-LevETIRAcetam for epilepsy), and cardiology (including Yorvipath® for hypoparathyroidism). Pendopharm also focuses on unmet medical needs through pediatric formulations (prpdp-AMLODIPINE, prpdp-LevETIRAcetam) and consumer health products (PHARIXIA, PrPERICHLOR®). The company operates primarily through distribution partnerships with international pharmaceutical companies to commercialize innovative medicines in Canada.

Differentiator

Problem solved

Functional benefit

Brands

  • PrPERICHLOR: Alcohol-free gingivitis oral rinse for professional treatment of moderate to severe gingivitis
  • Octasa
  • GLATECT
  • SportVis
  • prpdp-AMLODIPINE
  • ELEVIEW

Products and services

  • Yorvipath® (palopegteriparatide injection) Parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism in adults, developed by Ascendis Pharma and commercialized in Canada by Pendopharm under an exclusive distribution agreement.
  • Buccolam® Pediatric epilepsy treatment for buccal administration, commercialized in Canada by Pendopharm under an exclusive distribution agreement with Neuraxpharm.
  • Sebetralstat Investigational oral on-demand therapy for Hereditary Angioedema (HAE), distributed in Canada under exclusive agreement with KalVista Pharmaceuticals.
  • Cingal® / Monovisc® / Orthovisc® Hyaluronic acid-based viscosupplementation products for the treatment of osteoarthritis pain. Cingal is a next-generation single-injection non-opioid treatment; Monovisc and Orthovisc are single-injection viscosupplementation therapies.
  • Octasa® (oral mesalamine)

Quantifiable outcome

  • More than 40 specialty products across multiple therapeutic areas
  • +1 more outcomes

Companies that use Pendopharm

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Pendopharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pendopharm partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • NeuraxpharmcoreChannel Partner/ Reseller/ Distributor · 4 August 2025Exclusive distribution agreement for Buccolam in Canada. Buccolam received Health Canada approval and was commercialized in February 2026. Neuraxpharm is a pharmaceutical company specializing in CNS treatments.
  • KalVista PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 26 June 2025Exclusive distribution agreement for sebetralstat, an investigational oral therapy for Hereditary Angioedema (HAE). Under regulatory review in multiple countries, sebetralstat would become the first oral on-demand treatment for HAE in Canada. Financial terms not disclosed.
  • Ascendis Pharma A/ScoreChannel Partner/ Reseller/ Distributor · 9 July 2024Exclusive distribution agreement where Pendopharm is responsible for regulatory approval and commercialization of TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism in Canada. Yorvipath received Health Canada approval in February 2026. Ascendis is a global biopharma company headquartered in Copenhagen, Denmark (NASDAQ: ASND).
  • Anika Therapeutics Inc.coreChannel Partner/ Reseller/ Distributor · 16 May 2024Renewal of exclusive distribution agreement for Cingal, Monovisc, and Orthovisc through end of 2030. Partnership since 2012. Anika is a global joint preservation company (NASDAQ: ANIK) providing hyaluronic acid-based therapeutic solutions. Cingal is a next-generation non-opioid treatment for osteoarthritis pain.
  • Cosmo PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 31 July 2019Distribution partnership for ELEVIEW, the first all-in-one submucosal injectable composition for endoscopic resection procedures. Cosmo is a specialty pharma company focused on GI disorders and endoscopy. ELEVIEW is manufactured by Cosmo Technologies Ltd. in Dublin, Ireland and distributed by Pendopharm in Canada.
  • SynthonmajorChannel Partner/ Reseller/ Distributor · 29 September 2017Partnership for GLATECT (glatiramer acetate for injection) launch in Canada for treatment of relapsing-remitting multiple sclerosis. Synthon is an international pharma company headquartered in the Netherlands with products approved in over 90 countries.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Pendopharm competitors and assessment

Company assessment

Direct peers

  • Knight Therapeutics: Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products in Canada and select international markets. Highly comparable business model to Pendopharm with focus on specialty therapeutic areas and exclusive distribution agreements.
  • HLS Therapeutics: Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products for the North American market. Comparable specialty pharma distribution model with similar therapeutic focus areas including CNS and cardiology.
  • Cipher Pharmaceuticals: Canadian specialty pharmaceutical company that commercializes specialty products through licensing and distribution partnerships. Directly comparable to Pendopharm in business model, therapeutic focus, and Canadian market focus.
  • Acerus Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing novel prescription products. Similar size and Canadian market focus with licensing-driven business model.
  • Medison Pharma: Canadian-headquartered specialty pharma company that provides commercial access for innovative therapies in Canada and Israel. Closely comparable in-licensing and distribution model focused on specialty therapeutic areas.

Broad incumbents

  • Bausch Health (formerly Valeant Pharmaceuticals): Headquartered in Canada, Bausch Health is a large diversified specialty pharmaceutical company with significant Canadian operations. Comparable as a major Canadian pharma incumbent though much larger and broader in scope than Pendopharm.
  • AbbVie Canada: Major global pharmaceutical company with significant Canadian specialty pharma operations across immunology, neuroscience, and other therapeutic areas. Competes with Pendopharm's specialty portfolio offerings in Canada.
  • Takeda Canada: Canadian subsidiary of global pharma major Takeda, with strong specialty pharma presence in gastroenterology, neurology, and rare diseases. Directly overlaps with Pendopharm's core therapeutic areas.

Others

  • Innomar Strategies (AmerisourceBergen): Canadian specialty pharma services company providing commercialization, distribution, and patient support services. Comparable as a Canadian specialty pharma ecosystem participant, though services-focused rather than product-focused.

Regional players

  • JAMP Pharma Group: Canadian pharmaceutical company headquartered in Quebec (like Pendopharm) with broad generic and specialty pharmaceutical portfolio. Comparable Quebec-based Canadian pharma with similar market scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Pendopharm social profiles

Digital presence

Pendopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pendopharm leadership team

Management profile

Number of profiles

Profiles2 records

Pendopharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pendopharm M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pendopharm

What does Pendopharm do?

Pendopharm develops, in-licenses and commercializes specialty pharmaceutical products in Canada across four core therapeutic areas: gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Its portfolio of more than 40 specialty products includes branded prescription drugs (Yorvipath, GLATECT, Octasa, IBAVYR), viscosupplementation treatments (Cingal, Monovisc, Orthovisc, SportVis), endoscopic procedural products (ELEVIEW), pediatric formulations, and consumer oral-care brands. The company secures exclusive Canadian distribution rights from international innovators and manages regulatory approval, market access, and commercialization.

Is Pendopharm a public or private company?

Pendopharm is a private company. It is classified as corporate owned and is currently operating.

When was Pendopharm founded?

Pendopharm was founded in 2010. It employs 11 to 50 people.

Where is Pendopharm based?

Pendopharm is headquartered in Montreal, Canada, in the North America region.

How does Pendopharm make money?

Two revenue lines are on record. Specialty Pharmaceutical Product Sales are the primary driver. The others are exclusive Distribution Agreements.

Who are Pendopharm's main competitors?

Direct peers on record are Knight Therapeutics, HLS Therapeutics, Cipher Pharmaceuticals, Acerus Pharmaceuticals and Medison Pharma. Broad incumbents are Bausch Health (formerly Valeant Pharmaceuticals), AbbVie Canada and Takeda Canada. Innomar Strategies (AmerisourceBergen) is listed as an others. JAMP Pharma Group is listed as a regional player.

Does Pendopharm have an API?

No public API is recorded for Pendopharm.

What industry is Pendopharm in?

Pendopharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswirePendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in AdultsHealth Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone replacement therapy developed by Ascendis Pharma, for the treatment of chronic hypoparathyroidism in adults. The approval follows an exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for regulatory approval and commercialization of the drug in Canada. Pendopharm is now collaborating with partners to support market availability and achieve coverage through public and private drug plans.NewswirePendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to CanadaPendopharm, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals to manage regulatory approval and commercialization of sebetralstat, an investigational oral therapy for Hereditary Angioedema, in Canada. Sebetralstat is under regulatory review in multiple countries and is poised to become the first oral on-demand treatment for HAE in Canada, addressing a critical need for patients with this rare genetic disorder. Financial terms of the agreement were not disclosed.NewswirePendopharm is proud to launch an alcohol-free Antigingivitis Oral RinsePendopharm, a division of Pharmascience Inc., launched PrPERICHLOR WITHOUT ALCOHOL, an alcohol-free gingivitis mouthwash. The product is indicated for treatment of moderate to severe gingivitis and management of associated bleeding and inflammation between dental visits.PR NewswireEdesa Biotech Completes Financing to Develop Novel Dermatology and Anorectal TreatmentsEdesa Biotech Inc. completed a $7 million Series A financing led by Lumira Capital, with participation from Pharmascience Inc., Inveready Technology Investment Group, and Canadian family offices. The company also licensed its Canadian anorectal product rights to Pendopharm, a division of Pharmascience Inc. These funds will support the continued development of Edesa Biotech's innovative dermatology and gastroenterology pipeline.GlobeNewswireDGAP-News: PAION GRANTS LICENCE TO REMIMAZOLAM IN CANADA TO PENDOPHARMPAION AG signed a final license agreement granting Pendopharm an exclusive licence to develop and commercialize Remimazolam in Canada. PAION will receive milestone payments of CAD 5.7 million and tiered royalties starting at 15% on net sales. The deal follows an option agreement where Pendopharm committed to invest up to EUR 4 million in PAION shares.GlobeNewswireDGAP-News: PAION GRANTS PENDOPHARM EXCLUSIVE OPTION TO REMIMAZOLAM IN CANADAPAION and Pendopharm agreed on an exclusive license for Remimazolam in Canada, with Pendopharm committing up to EUR 4 million in a rights offering. PAION will receive CAD 5.7 million in milestone payments and tiered royalties starting at 15%.GlobeNewswireDGAP-Adhoc: PAION GRANTS PENDOPHARM EXCLUSIVE OPTION TO REMIMAZOLAM IN CANADAPAION and Pendopharm agreed on an exclusive license for Remimazolam in Canada, with PAION receiving up to CAD 5.7 million in milestone payments and tiered royalties starting at 15%. Pendopharm's affiliate committed to invest up to EUR 4 million in PAION's rights offering, subject to the offering's success.